BIOGEN INC. is 18.0x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($29.53 B vs $1.64 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TSHA | BIIB |
|---|---|---|
| Market cap | $1.64 B | $29.53 B |
| US-listed rank | #2266 | #476 |
| Revenue (latest FY) | $9.77M | $9.89B |
| Net income (latest FY) | -$109.00M | $1.29B |
| Net margin | -1115.3% | 13.1% |
| P/E (trailing FY) | - | 22.8 |
| SEC filings | 386 | 2,690 |
BIOGEN INC. is 18.0x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($29.53 B vs $1.64 B).
In their latest fiscal years, Taysha Gene Therapies, Inc. reported $9.77M in revenue while BIOGEN INC. reported $9.89B.
Full pages: Taysha Gene Therapies, Inc. and BIOGEN INC., or browse the full rankings.